Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation–Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105

PURPOSE: This study was designed to assess efficacy, safety, and predictors of response to iniparib in combination with gemcitabine and carboplatin in early-stage triple-negative and BRCA1/2 mutation–associated breast cancer. PATIENTS AND METHODS: This single-arm phase II study enrolled patients wit...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Clin Oncol
Egile Nagusiak: Telli, Melinda L., Jensen, Kristin C., Vinayak, Shaveta, Kurian, Allison W., Lipson, Jafi A., Flaherty, Patrick J., Timms, Kirsten, Abkevich, Victor, Schackmann, Elizabeth A., Wapnir, Irene L., Carlson, Robert W., Chang, Pei-Jen, Sparano, Joseph A., Head, Bobbie, Goldstein, Lori J., Haley, Barbara, Dakhil, Shaker R., Reid, Julia E., Hartman, Anne-Renee, Manola, Judith, Ford, James M.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Clinical Oncology 2015
Gaiak:
ORIGINAL REPORTS
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4451172/
https://ncbi.nlm.nih.gov/pubmed/25847929
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.57.0085
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak